Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 1/2 study of sabestomig (AZD7789) in advanced or metastatic solid tumors
NL-OMON60759Phase 2Completed
- Sponsor
- AstraZeneca
- Start
- Sep 2022
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of sabestomig in non-small cell lung cancer (NSCLC), gastric adenocarcinoma, gastroesophageal junction adenocarcinoma and 1 more (6 arms), sponsored by AstraZeneca. Primary endpoints: Safety and tolerability and Objective response rate. Started Sep 2022; status: completed.
02
Drugs
sabestomig
03
Conditions
non-small cell lung cancer (NSCLC)gastric adenocarcinomagastroesophageal junction adenocarcinomaNonhematologic neoplasms
Beyond the preview
Go deeper on NL-OMON60759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON60759.